Partners & Licensees Pipeline
Partnering the NAV Technology Platform
PARTNERS & LICENSEES PIPELINE

PROGRAM AREA | RESEARCH | PRECLINICAL | PHASE I/II | PHASE III | APPROVED | LICENSEE | PHASE | |
---|---|---|---|---|---|---|---|---|
Central Nervous System |
![]() |
APPROVED | ||||||
![]() |
PHASE III | |||||||
![]() |
PHASE I/II | |||||||
![]() |
PHASE I/II | |||||||
![]() |
PHASE I/II | |||||||
![]() |
PRECLINICAL | |||||||
![]() |
PRECLINICAL | |||||||
![]() |
PRECLINICAL | |||||||
![]() |
PRECLINICAL | |||||||
![]() |
PRECLINICAL | |||||||
![]() |
RESEARCH | |||||||
![]() |
RESEARCH | |||||||
![]() |
RESEARCH | |||||||
Hematologic/Liver |
![]() |
PHASE I/II | ||||||
![]() |
PHASE I/II | |||||||
![]() |
PHASE I/II | |||||||
![]() |
PHASE I/II | |||||||
![]() |
PRECLINICAL | |||||||
![]() |
RESEARCH | |||||||
Cardiac / Skeletal Muscle |
![]() |
PHASE III | ||||||
![]() |
PHASE I/II | |||||||
![]() |
PHASE I/II |
Zolgensma® is approved in the U.S. for the treatment of pediatric patients less than 2 years of age with SMA with bi-allelic mutations in the SMN1 gene.
©2021 REGENXBIO Inc. “NAV®” is a registered trademark of REGENXBIO Inc. All rights reserved.
|
Recent Comments